May 30, 1991 |
More than a year ago, sister drug companies in the United States and Canada first laid plans to enter the health marketplace with a low-cost generic equivalent for the most widely used AIDS drug, AZT. Now, with the federal government adding weight to their efforts to break the monopoly held by AZT's manufacturer, Burroughs Wellcome Co., they may get the chance, slicing the cost of the life-extending drug as much as 75% in the process.
August 15, 2006 |
Bristol-Myers Squibb Co. and Sanofi-Aventis said Monday that they filed for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of blood thinner Plavix and force it to recall product already sold. The companies also said they had begun discounting Plavix to stem the loss of market share. A hearing on the motion is set for Friday in the U.S.
December 9, 2006 |
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
June 6, 2006 |
Allergan Inc., maker of the Botox wrinkle treatment, said the Food and Drug Administration approved its Juvederm dermal filler treatment targeting the folds alongside the nose and mouth. Separately, Allergan said it won a court ruling that would block Apotex Inc. from selling a generic version of a treatment for eye inflammation until 2009.
May 31, 2007 |
Bristol-Myers Squibb Co. was charged with lying to federal regulators over the bungled patent settlement for the drug maker's blood-thinner Plavix, a planned first step toward it pleading guilty in the case. A two-count criminal charge was filed in federal court in Washington. The company said May 10 that it would plead guilty to two counts of making false statements and pay a $1-million fine.
August 18, 2006 |
Bristol-Myers Squibb Co. and Sanofi-Aventis won U.S. regulatory approval for the use of their blood thinner Plavix after severe heart attacks. The benefit to the drug makers may be limited because Apotex Inc. last week started marketing a cheaper copy of Plavix, the world's second-biggest-selling drug behind Pfizer Inc.'s Lipitor cholesterol pill. A U.S. court today will hear Sanofi and Bristol-Myers' request to bar Apotex's product. At stake is $6.3 billion in annual revenue.